Professor Bryan Morton founded EUSA Pharma, Inc. a transatlantic speciality pharmaceutical company focused on oncology and critical care. Bryan was the President and CEO of EUSA from 2006 until the sale of the company to Jazz Pharmaceuticals in 2012 for a total consideration of $700m. In March 2015, Bryan, together with Essex Woodlands, reacquired certain EUSA assets from Jazz Pharmaceuticals in order to create a new speciality Pharma company, trading once again as EUSA Pharma. This company was sold for $900m in 2022 to Recordati. Prior to founding the original EUSA Pharma, Bryan was the CEO of Zeneus Pharma, which he founded following the $120m acquisition of Elan’s European business. Zeneus was subsequently acquired by Cephalon in late 2005 for $360m after two highly successful years of rapid growth and profitable trading. Bryan’s entrepreneurial success is built on 30 years of commercial business development and general management experience in the pharmaceutical industry, spent largely with Merck & Co Inc. and Bristol Myers Squibb. He has extensive international experience, particularly in the US and Europe, having held senior positions, including at Board and SVP level, in America, the UK, Belgium and Australia. Bryan is Chairman of a new Venture Capital firm, Nodenza Ventures, and holds the position of Operating Partner at the Private Equity firm EW Healthcare Partners. He is also Executive Chairman of Izana Bioscience. Bryan has an MBA from Durham University and is an Honorary Professor at Durham University. Bryan also holds a BSc in Pharmacology from Aberdeen University in Scotland and is a graduate of the INSEAD European Management Programme. Bryan was awarded a CBE in the Queen’s Birthday Honours list in 2016 for services to the healthcare industry. In his spare time, Bryan enjoys his hobby of flying and is a qualified Commercial Pilot and Flight Instructor. He played International Rugby when at University having played for two seasons with the Scottish Universities team.
Visit Bryan’s LinkedIn page here.